FDA Terminates Arthritis Advisory Committee as Obsolete
Published Date: 7/30/2025
Notice
Summary
The FDA is ending its Arthritis Advisory Committee because it’s no longer needed. This change affects committee members and anyone who followed its advice, but it won’t cost extra or cause delays. The decision is effective immediately, streamlining how the FDA handles arthritis-related reviews.
No Economic Impacts Identified for this Document
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in